Clinical Trial Update: Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dendritic cell/myeloma fusion vaccines in combination with nivolumab for relapsed multiple myeloma; study terminated with posted result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2022-09-01